CN118159565A - 结合gprc5d的抗体及其用途 - Google Patents

结合gprc5d的抗体及其用途 Download PDF

Info

Publication number
CN118159565A
CN118159565A CN202280073069.XA CN202280073069A CN118159565A CN 118159565 A CN118159565 A CN 118159565A CN 202280073069 A CN202280073069 A CN 202280073069A CN 118159565 A CN118159565 A CN 118159565A
Authority
CN
China
Prior art keywords
seq
amino acid
variable region
acid sequence
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280073069.XA
Other languages
English (en)
Chinese (zh)
Inventor
陆臻桢
王玉洁
彭双莉
张正平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of CN118159565A publication Critical patent/CN118159565A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202280073069.XA 2021-11-05 2022-11-04 结合gprc5d的抗体及其用途 Pending CN118159565A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2021113051497 2021-11-05
CN202111305149 2021-11-05
PCT/CN2022/129803 WO2023078382A1 (zh) 2021-11-05 2022-11-04 结合gprc5d的抗体及其用途

Publications (1)

Publication Number Publication Date
CN118159565A true CN118159565A (zh) 2024-06-07

Family

ID=86240662

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280073069.XA Pending CN118159565A (zh) 2021-11-05 2022-11-04 结合gprc5d的抗体及其用途

Country Status (7)

Country Link
US (1) US20260159583A1 (cg-RX-API-DMAC7.html)
EP (1) EP4428153A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024540148A (cg-RX-API-DMAC7.html)
KR (1) KR20240099351A (cg-RX-API-DMAC7.html)
CN (1) CN118159565A (cg-RX-API-DMAC7.html)
TW (1) TW202334222A (cg-RX-API-DMAC7.html)
WO (1) WO2023078382A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116925229B (zh) * 2023-09-19 2023-12-15 南京驯鹿生物技术股份有限公司 一种靶向gprc5d的抗体及其应用
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
US12545726B1 (en) 2025-07-22 2026-02-10 Integral Molecular, Inc. Compositions and methods related to GPRC5D binding agents and variants thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107206077A (zh) * 2014-12-05 2017-09-26 纪念斯隆-凯特琳癌症中心 靶向g‑蛋白偶联受体的抗体和使用方法
CN109715667A (zh) * 2016-07-20 2019-05-03 詹森药业有限公司 抗-gprc5d抗体、结合gprc5d和cd3的双特异性抗原结合分子及其用途
CN110462038A (zh) * 2017-02-07 2019-11-15 第一三共株式会社 抗gprc5d抗体和包含所述抗体的分子
US20210054094A1 (en) * 2018-02-09 2021-02-25 Hoffmann-La Roche Inc. Antibodies binding to gprc5d
EA202092753A1 (ru) * 2019-05-02 2021-03-12 Янссен Байотек, Инк. Биспецифические антитела к bcma/cd3 и gprdc5d/cd3 для применения в лечении рака

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12077592B2 (en) * 2019-01-18 2024-09-03 Janssen Biotech, Inc. GPRC5D chimeric antigen receptors and cells expressing the same
JP2022543553A (ja) * 2019-07-31 2022-10-13 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Gprc5dに結合する抗体

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107206077A (zh) * 2014-12-05 2017-09-26 纪念斯隆-凯特琳癌症中心 靶向g‑蛋白偶联受体的抗体和使用方法
CN109715667A (zh) * 2016-07-20 2019-05-03 詹森药业有限公司 抗-gprc5d抗体、结合gprc5d和cd3的双特异性抗原结合分子及其用途
CN110462038A (zh) * 2017-02-07 2019-11-15 第一三共株式会社 抗gprc5d抗体和包含所述抗体的分子
US20210054094A1 (en) * 2018-02-09 2021-02-25 Hoffmann-La Roche Inc. Antibodies binding to gprc5d
EA202092753A1 (ru) * 2019-05-02 2021-03-12 Янссен Байотек, Инк. Биспецифические антитела к bcma/cd3 и gprdc5d/cd3 для применения в лечении рака

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HE HUANG;HENG-WEI WU;YONG-XIAN HU;: "嵌合抗原受体T细胞在治疗难治/复发多发性骨髓瘤中的新进展(英文)", JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B(BIOMEDICINE & BIOTECHNOLOGY), no. 01, 3 January 2020 (2020-01-03) *
TATSUSHI ET AL: "Anti-GPRC5D/CD3 bispecific T-cell-redirecting antibody for the treatment of multiple myeloma", MOLECULAR CANCER THERAPEUTICS, vol. 18, no. 9, 1 September 2019 (2019-09-01) *

Also Published As

Publication number Publication date
EP4428153A1 (en) 2024-09-11
JP2024540148A (ja) 2024-10-31
TW202334222A (zh) 2023-09-01
US20260159583A1 (en) 2026-06-11
KR20240099351A (ko) 2024-06-28
WO2023078382A1 (zh) 2023-05-11
EP4428153A4 (en) 2026-02-11

Similar Documents

Publication Publication Date Title
JP7317272B2 (ja) Tigit抗体、その抗原結合断片及びその医療用途 本願は、2019年9月29日に出願された出願番号cn201710908565.3に基づいたものであり、その優先権を主張する。その開示は、その全体が参照により本明細書に組み込まれる。
EP4428153A1 (en) Antibody binding to gprc5d and use thereof
CN112703013B (zh) Cd3抗原结合片段及其应用
US20250145705A1 (en) Gprc5d antibody and application thereof
US20240309087A1 (en) Anti-cd112r antibody and use thereof
CN113906053B (zh) 抗cea抗体及其应用
EP4663661A1 (en) Anti-cdh6 antibody and use thereof
TW202128765A (zh) 一種雙特異性抗體
KR20250017233A (ko) 항-bdca2 항체 및 이의 용도
CN113840836B (zh) 抗结缔组织生长因子抗体及其应用
EP4410840A1 (en) Bispecific antibody and application thereof
AU2024331841A1 (en) Antibody targeting receptor tyrosine kinase-like orphan receptor 1 and use thereof
WO2024012513A1 (en) Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
CN110606892B (zh) 一种高亲和力高生物活性的lag-3抗体及其应用
AU2024260168A1 (en) Bispecific antibody targeting g protein-coupled receptor
WO2025035451A1 (zh) 抗cd93抗体、其组合物及用途
CN118556082A (zh) p95HER2抗体及其应用
CN119604529A (zh) 抗体、其抗原结合片段及其药物用途
WO2023178645A1 (zh) 靶向cd3的抗体及其应用
CN116848144A (zh) 抗pd-l1抗体及其用途
CN115028722B (zh) 抗tslp抗体及其制备方法和用途
RU2817143C2 (ru) Антитело против cd79b, его антигенсвязывающий фрагмент и его фармацевтическое применение
CA3282551A1 (en) Anti-cdh6 antibody and use thereof
KR20240099470A (ko) 항-cldn18.2 단일클론 항체 및 이의 응용
JP2025535498A (ja) Cd24に対する抗体およびその使用

Legal Events

Date Code Title Description
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination